Cooley LLP announced today that it advised Kite Pharma, Inc. on its $146.6 million IPO. Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company now trades on The NASDAQ Global Select Market under the symbol “KITE.”
The Cooley corporate securities team was comprised of partners Fred Muto (head of the firm’s business department), Charlie Kim and Charles Bair, and associates Veer Bhavnagri, Kristin VanderPas, Rebecca Jones and Katherine Decker-Sadowski. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); special counsel Laura McDaniels (compensation and benefits); and partner Susan Philpot (tax).
Related Posts:
- Cooley Advises Underwriters on Five Prime Therapeutics IPO
- Cooley Advises Xencor on its Initial Public Offering
- Invitae Completes $117 Million Initial Public Offering
- Cooley Advises Underwriters on HealthEquity’s $146.5 Million IPO
- Dermira Prices its Initial Public Offering
